<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic evaluation for patients with suspected NORSE (including FIRES)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic evaluation for patients with suspected NORSE (including FIRES)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Diagnostic evaluation for patients with suspected NORSE (including FIRES)</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="85%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Screen</td> <td class="subtitle1_left">Disease/agent tested</td> </tr> <tr> <td> <p><strong>Section.1</strong></p> <strong>Initial workup</strong></td> <td>Recommended in most or all patients: <ul class="decimal_heading"> <li><strong>Whole blood/serum:</strong> CBC, bacterial and fungal cultures, RPR-VDRL, HIV-1/2 immunoassay with confirmatory viral load if appropriate.</li> <li><strong>Serum:</strong> IgG and IgM testing (acute and convalescent) for C<em>hlamydia pneumoniae</em>, <em>Bartonella henselae</em>, <em>Mycoplasma pneumoniae</em>, <em>Coxiella burnetii</em>, <em>Shigella</em> species and <em>Chlamydia psittaci</em>.</li> <li><strong>Nares or nasopharyngeal swab (the latter preferred):</strong> Respiratory viral DFA panel; SARS-CoV-2 PCR.</li> <li><strong>CSF:</strong> <ul> <li>Cell counts; protein; and glucose, bacterial, and fungal stains and cultures.</li> <li>RT-PCR for HIV; PCR for HSV1, HSV2, VZV, EBV, MTb; consider WNV, VDRL, encephalitis panel.</li> <li>PCR for <em>C. pneumoniae</em> and <em>psittaci</em>, <em>B. henselae</em>, <em>M. pneumoniae</em>, <em>C. burnetti</em> and <em>Shigella</em> species.</li> <li>Autoimmune epilepsy panel (refer to section 2).</li> <li>Consider metagenomics for any nonhuman nucleic acid material.</li> <li>Consider cytokine profile (section 7).</li> <li>Consider cytology and flow cytometry.</li> </ul> </li> </ul> <p class="extra_spacing_top">Recommended in immunocompromised patients:</p> <ul class="decimal_heading"> <li><strong>Serum:</strong> IgG <em>Cryptococcus</em> species, IgM and IgG <em>Histoplasma capsulatum</em>, IgG <em>Toxoplasma gondii</em>.</li> <li><strong>Sputum:</strong> MTb Gene Xpert.</li> <li><strong>CSF:</strong> Eosinophils, silver stain for CNS fungi, PCR for JC virus, CMV, EBV, HHV6, EEE, enterovirus, influenza A/B, HIV, WNV, parvovirus, listeria Ab, measles (rubeola).</li> <li><strong>Stool:</strong> Adenovirus PCR, enterovirus PCR.</li> </ul> <p class="extra_spacing_top">Recommended if geographic/seasonal/occupational risk of exposure:</p> <ul class="decimal_heading"> <li>Serum buffy coat and peripheral smear.</li> <li>Lyme EIA with IgM and IgG reflex.</li> <li>Hepatitis C immunoassay and viral load if appropriate.</li> <li>Send further serum and CSF samples to CDC DVBID Arbovirus Diagnostic Laboratory, CSF and serum rickettsial disease panel, flavivirus panel, bunyavirus panel.</li> <li>Serum testing for<em> Acanthamoeba</em> spp., <em>Balamuthia mandrillaris</em>, <em>Baylisascaris procyonis</em>.</li> <li>Other.</li> </ul> <p class="extra_spacing_top">Consider <strong>CSF Metagenomics</strong> for any infectious genetic material.</p> </td> </tr> <tr> <td rowspan="2"> <p><strong>Section.2</strong></p> <p><strong>Autoimmune/<br/> paraneoplastic</strong></p> </td> <td>Recommended: <ul class="decimal_heading"> <li><strong>Serum and CSF paraneoplastic and autoimmune epilepsy antibody panel</strong><br/> To include antibodies to: LGI-1, CASPR2, Ma1, Ma2/TaDPPX, GAD65, NMDA, AMPA, GABA-B, GABA-A, glycine receptor, Tr, amphiphysin, CV-2/CRMP-5, Neurexin-3alpha, adenylate kinase, anti-neuronal nuclear antibody types 1/2/3 (Hu, Yo and Ri), Purkinje cell cytoplasmic antibody types 1,2, GFAP-alpha, anti-SOX1, N-type calcium Ab, PQ-type calcium channel, Acetylcholine receptor (muscle) binding Ab, Ach-R ganglionic neuronal Ab, AQP4, MOG Ab, IgLON5 Ab, D2R Ab.</li> <li><strong>Additional serologic studies - Serum</strong> (likely not pathogenic but hint towards an autoimmune etiology)<br/> ANA (detection and identification), ANCA, anti-thyroid antibodies (anti-thryoglobulin, anti-TPO), anti-endomysial, ESR, CRP, SPEP, IFE, RA, ACE, cold and warm agglutinins, tests for MAS/HLH (serum triglycerides and sIL2-r, ferritin).</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Suggestion: Store extra frozen CSF and serum for possible further autoimmune testing in a research lab.</strong></td> </tr> <tr> <td rowspan="2"> <p><strong>Section.3</strong></p> <strong>Neoplastic</strong></td> <td>Recommended: <ul class="decimal_heading"> <li>CT chest/abdomen/pelvis, pelvic or scrotal ultrasound, mammogram, CSF cytology, flow cytometry, cancer serum markers. Pelvic MRI. Whole body PET-CT if above tests are not conclusive.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Optional: Bone marrow biopsy.</td> </tr> <tr> <td rowspan="2"> <p><strong>Section.4</strong></p> <strong>Metabolic</strong></td> <td>Recommended: <ul class="decimal_heading"> <li><strong>Whole blood/serum:</strong> BUN/Cr, LDH, liver function tests, electrolytes, Ca/Mg/Phos, ammonia.</li> <li><strong>Urine:</strong> Porphyria screen (spot urine), UA with microscopic urinalysis.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Consider: Vitamin B1 level, B12 level, homocysteine, folate, lactate, pyruvate, CK, troponin; tests for mitochondrial disorder (lactate, pyruvate, MR spectroscopy, muscle biopsy).</td> </tr> <tr> <td rowspan="2"> <p><strong>Section.5</strong></p> <strong>Toxicologic</strong></td> <td>Recommended: <ul class="decimal_heading"> <li>Benzodiazepines, amphetamines, cocaine, fentanyl, alcohol, ecstasy, heavy metals, synthetic cannabinoids, bath salts.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Consider: Extended opiate and overdose panel, LSD, heroin, PCP, marijuana.</td> </tr> <tr> <td> <p><strong>Section.6</strong></p> <strong>Genetics</strong></td> <td> <p>Consider: Obtain genetics consult, if possible. Genetic screens for mitochondrial disorders (MERRF, MELAS, POLG1, SURF1, MT-ATP6) and VLCFA screen. Consider ceruloplasmin and 24-hour urine copper.</p> Consider mendeliome or whole exome sequencing (also look for gene polymorphisms in IL-1beta, IL-6, IL-10, TNF-alpha, HMGB1, TLR4, IL-1RN, SCN1A, and SCN2A), mitochondrial genome sequencing, and CGH array.</td> </tr> <tr> <td> <p><strong>Section.7</strong></p> <strong>Cytokine assay</strong></td> <td><strong>Serum and CSF:</strong> <ul class="decimal_heading"> <li>Cytokine assay for quantitative measure of IL‐1beta, IL-1Ra, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12, IL-17, granulocyte‐macrophage colony stimulating factor, tumor necrosis factor‐alpha, HMGB1, CCL2, CXCL8, CXCL9, CXCL10, CXCL11.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>At 48 hours:</strong>
<ul class="decimal_heading">
<li>Assess returned test results, initiate appropriate treatments.</li>
<li>If patient continues to have refractory status epilepticus or coma, transfer to higher level of care for appropriate further treatment of NORSE at a center with experience in these cases, including continuous video-EEG monitoring.</li>
</ul>
<p class="extra_spacing_top"><strong>At 72 hours:</strong></p>
<ul class="decimal_heading">
<li>Consider initiation of high-dose parenteral corticosteroids. Transfer to higher level of care for consideration of IVIG, plasmapheresis, or further immunomodulatory therapy if no clear diagnosis, if still having seizures, if no continuous EEG monitoring available, or if still comatose.</li>
</ul></div><div class="graphic_footnotes">NORSE: new-onset refractory status epilepticus; FIRES: febrile infection-related epilepsy syndrome; CBC: complete blood count; RPR-VDRL: rapid plasma reagin-Venereal Disease Research Laboratory; HIV: human immunodeficiency virus; IgG: immunoglobulin G; IgM: immunoglobulin M; DFA: direct fluorescent antibody; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; PCR: polymerase chain reaction; CSF: cerebrospinal fluid; RT-PCR: reverse transcriptase-polymerase chain reaction; HSV1: herpes simplex virus type 1; HSV2: herpes simplex virus type 2; VZV: varicella zoster virus; EBV: Epstein-Barr virus; MTb: Mycobacterium tuberculosis; WNV: West Nile virus; CNS: central nervous system; JC virus: John Cunningham virus (human polyomavirus 2); CMV: cytomegalovirus; HHV6: human herpes virus 6; EEE: eastern equine encephalitis; listeria Ab: listeria antibody; EIA: enzyme immunoassay; CDC DVBID: Centers for Disease Control and Prevention Division of Vector-Borne Diseases; spp.: species; ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibody; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SPEP: serum protein electrophoresis; IFE: immunofixation; RA: rheumatoid arthritis; ACE: angiotensin-converting-enzyme; MAS/HLH: macrophage activation syndrome/hemophagocytic lymphohistiocytosis; sIL2-R: soluble interleukin-2 receptor; CT: computed tomography; MRI: magnetic resonance imaging; PET-CT: positron emission tomography-CT; BUN/Cr: blood urea nitrogen/creatinine ratio; LDH: lactate dehydrogenase; Ca/Mg/Phos: calcium, magnesium, and phosphate; UA: urinalysis; CK: creatine kinase; LSD: lysergic acid diethylamide; PCP: phencyclidine; MERRF: mitochondrial encephalopathy with ragged red fibers; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; VLCFA: very long-chain fatty acids; CGH: comparative genomic hybridization; EEG: electroencephalography; IVIG: intravenous immune globulin.</div><div class="graphic_reference">Reproduced with permission from: Gaspard N, Sculier C, Hirsch LJ, et al. NORSE (including FIRES) diagnostic evaluation. NORSE Institute. www.norseinstitute.org. Copyright © 2020 NORSE Institute.</div><div id="graphicVersion">Graphic 140710 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
